Table 9.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1992 to 2001

Recipients with Liver Transplants

		Year of Transplant
		1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Transplants		3,064	3,440	3,652	3,934	4,080	4,186	4,517	4,744	4,979	5,187
Tx with Antirejection Treatments		1,452	1,707	1,566	1,338	1,308	1,333	1,187	1,480	1,511	1,427
Antibodies	Category Usage	33.1%	35.4%	30.3%	21.9%	13.3%	12.1%	13.1%	12.4%	14.4%	16.7%
	ALG	0.1%	0.7%	1.4%	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG	0.6%	2.7%	2.4%	1.4%	2.0%	1.4%	1.3%	0.6%	0.5%	0.5%
	NRATG/NRATS	0.0%	0.0%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.0%	0.0%
	OKT3	32.9%	33.5%	28.0%	20.4%	11.9%	11.1%	9.7%	6.8%	6.2%	6.7%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.3%	1.4%	3.2%	5.1%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.9%	1.7%	2.4%	1.6%
	Simulect	0.0%	0.0%	0.1%	0.0%	0.0%	0.1%	1.2%	3.0%	3.1%	4.2%
Corticosteroids	Category Usage	94.2%	89.0%	86.0%	83.6%	83.7%	83.7%	87.1%	89.3%	90.7%	88.9%
	Steroids	94.2%	89.0%	86.0%	83.6%	83.7%	83.7%	87.1%	89.3%	90.7%	88.9%

Source: OPTN/SRTR Data as of August 1, 2003.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.